BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 7
• 9
• 10
• 11
• 12
• 13
• 14
• 17
• 18
• 19
• 20
• 21
• 24
• 25
• 26
• 27
• 28

• 

  Business

  Philadelphia’s Life Sciences Scene Making Its Mark

  The Philadelphia market has gained recognition not only for its cell and gene therapy sector but also its real estate scene and talent pool. Vittoria Biotherapeutics, Interius BioTherapeutics and Chamber of Commerce for Greater Philadelphia executives share why the area is a life sciences hot spot.

  February 20, 2025

   · 

  7 min read

   · 

  Angela Gabriel
• 

  Government

  FTC Doubles Down on Tighter Merger Rules Despite Trump’s Pro-Industry Posture

  Despite expectations of dealmaking leniency, new FTC chairman Andrew Ferguson told staff that he will retain the current 2023 FTC and DOJ guidelines on mergers, upholding stricter anti-trust scrutiny on deals.

  February 20, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Job Trends

  6 Companies Hiring in Pennsylvania

  Looking for a biopharma job in Pennsylvania? Check out the BioSpace list of six companies hiring life sciences professionals like you.

  February 20, 2025

   · 

  1 min read

   · 

  Angela Gabriel
• 

  Regulatory

  FDA Kicks Down Harmony’s Bid to Push Wakix Into Idiopathic Hypersomnia

  Despite the regulatory setback, analysts appear optimistic, noting that Harmony’s long-term prospects remain bright given the development of its high-dose formulation of its sleep-regulating drug Wakix.

  February 20, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Business

  Newly Stacked PhRMA to Meet With Trump on IRA, Other Policies

  The meeting, which will include Pfizer CEO Albert Bourla as the newly named board of directors’ chair, will reportedly cover key topics for the lobbying group, including the Inflation Reduction Act.

  February 20, 2025

   · 

  2 min read

   · 

  Kate Goodwin
• 

  Depression

  Supernus Falls Back on CNS Portfolio as Depression Drug Fails Mid-Stage Study

  After SPN-820’s failure, Supernus is relying on its non-stimulant ADHD drug Qelbree and the recently approved Parkinson’s therapy Onapgo to sustain the company.

  February 20, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  FDA

  FDA Reels From ‘Indiscriminate’ Job Cuts Under Trump as Biopharma Appeals for Clarity

  Morale is low at the FDA, which was hit with layoffs this week following RFK Jr.’s confirmation. Biopharma leaders and agency insiders fear further workforce cuts could delay new medicines.

  February 20, 2025

   · 

  5 min read

   · 

  Heather McKenzie
• 

  Earnings

  BridgeBio Stock Hits 1-Year High as Attruby Rx Numbers Double

  BridgeBio beat investor expectations with 1,028 unique prescriptions for ATTR-CM therapy Attruby, setting the company up to beat a 2025 sales consensus of $86 million.

  February 20, 2025

   · 

  2 min read

   · 

  Annalee Armstrong
• 

  Mergers & acquisitions

  AstraZeneca Buys FibroGen’s China Unit for $160M as Probes Continue

  A year ago, AstraZeneca walked away from the bulk of its roxadustat partnership with FibroGen—though the pharma at the time decided to retain its relationship with the biotech’s China operations.

  February 20, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  NaviFUS Corp. Leverages Taiwan’s Advanced Chip Technology to Lead Non-Invasive Precision Medicine for Brain Disorders

  February 20, 2025

   · 

  3 min read